Recent Finacing
Recent Raise
CytoAgents is a clinical-stage biotech developing an oral small-molecule cytokine-release modulator (GP1681) to treat CRS across CAR‑T, bispecific antibody therapies and respiratory infections, now in Phase 1/2 trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at CytoAgents.
